<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Lewy body on Agnès Pérez-Millan</title>
    <link>https://Agnes2.github.io/tags/lewy-body/</link>
    <description>Recent content in Lewy body on Agnès Pérez-Millan</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 01 Apr 2024 00:00:00 +0000</lastBuildDate><atom:link href="https://Agnes2.github.io/tags/lewy-body/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Impact of demographics and comorbid conditions on plasma biomarkers concentrations and their diagnostic accuracy in a memory clinic cohort</title>
      <link>https://Agnes2.github.io/publications/2024-plasma/</link>
      <pubDate>Mon, 01 Apr 2024 00:00:00 +0000</pubDate>
      
      <guid>https://Agnes2.github.io/publications/2024-plasma/</guid>
      <description>Jordi Sarto, Diana Esteller-Gauxax, Adrià Tort-Merino, Núria Guillén, Agnès Pérez‐Millan, Neus Falgàs, Sergi Borrego-Écija, Guadalupe Fernández-Villullas, Beatriz Bosch, Jordi Juncà-Parella, Anna Antonell, Laura Naranjo, Raquel Ruiz-García, Josep María Augé, Raquel Sánchez-Valle, Albert Lladó, Mircea Balasa. Journal of Neurology.
ABSTRACT
Plasma biomarkers have emerged as promising tools for identifying amyloid beta (Aβ) pathology. Before implementation in routine clinical practice, confounding factors modifying their concentration beyond neurodegenerative diseases should be identified. We studied the association of a comprehensive list of demographics, comorbidities, medication and laboratory parameters with plasma p-tau181, glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) on a prospective memory clinic cohort and studied their impact on diagnostic accuracy for discriminating CSF/amyloid PET-defined Aβ status.</description>
    </item>
    
  </channel>
</rss>
